These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20888739)

  • 1. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 4. Statistical challenges in a regulatory review of cardiovascular and CNS clinical trials.
    Hung HM; Wang SJ; Yang P; Jin K; Lawrence J; Kordzakhia G; Massie T
    J Biopharm Stat; 2016; 26(1):37-43. PubMed ID: 26366624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive Beers criteria: limitations.
    Linnebur SA; Vande Griend JP; Dugan JP; Page RL
    Consult Pharm; 2009 Nov; 24(11):792; author reply 792, 794. PubMed ID: 20092217
    [No Abstract]   [Full Text] [Related]  

  • 7. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of predictive models in CNS diseases.
    Gomeni R
    Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs and mood changes.
    Kitchen I
    Nursing (Lond); 1984 Apr; 2(24):719-21. PubMed ID: 6563458
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 17. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adaptive designs for clinical trial].
    Li W; He SJ; Wang Y; Cheng XR; Jia X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jun; 28(6):605-7. PubMed ID: 17939395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Trials in CNS - SMi conference.
    Filson S
    IDrugs; 2007 Jan; 10(1):23-5. PubMed ID: 17187309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.